AICAR

AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) is a nucleotide analog and AMPK agonist that mimics cellular energy stress, leading to enhanced fat oxidation, glucose uptake, and endurance capacity. It has been studied in metabolic and athletic contexts for its ability to trigger exercise-like effects without physical activity. AICAR is also used experimentally for improving mitochondrial function and insulin sensitivity. Best suited for short-term cycles with careful monitoring to avoid over-activation of AMPK. All data is based on animal or cellular models.

• AMPK Activation
• Mimics exercise-induced energy changes

• unit: mg

  low dose: 30

  frequency: Once

  high dose: 100

  standard dose: 50

  administration route: Intravenous (IV)

• Administer 50 mg/kg IV once daily, commonly in the morning or before exercise. Cycle for 4–8 weeks, followed by an equal or longer off period. Do not exceed 8-week continuous cycles due to potential AMPK desensitization. Often used in metabolic or endurance performance protocols.

long term: ["Remains experimental; no confirmed clinical benefit in humans established, long-term risks unknown"]

sequence: Not applicable

half life: Approximately 1-1.5 hours IV in animal studies.

degradation: Metabolized primarily in the liver with renal excretion.

molecular weight: 258.23

molecular formula: C9H14N4O5

tissue specificity: Primarily affects muscle and liver tissues.

• Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy by Regulating Mitophagy.preclinicalPMID 39795939 ↗
• AMPK activation by AICAR reduces diet induced fatty liver in C57BL/6 mice.preclinicalPMID 36913846 ↗
• AICAR and Metformin Exert AMPK-dependent Effects on INS-1E Pancreatic beta-cell Apoptosis.mechanismPMID 26435693 ↗